Altre lingue Carna Biosciences, Inc.

Azioni

4572

JP3220550002

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 16/07/2024			Variaz. 5gg	Var. 1 gen.
408 ^JPY	+0,49%		+8,80%	-21,84%

07/03	Fresh Tracks Therapeutics, Inc. e Carna Biosciences, Inc. stipulano l'Accordo di Licenza per la Cessazione	CI
2023	Carna Biosciences, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Carna Biosciences, Inc. announced that it has received ¥362.07 million in funding from Athos Capital Limited	31/05
Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited	15/05
Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	07/03
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23
Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.	08/12/22
Carna Biosciences, Inc. announced that it expects to receive Ã‘11.209315 million in funding from Cantor Fitzgerald & Co.	22/11/22
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	10/05/22
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases	02/02/22
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc	02/02/22
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	06/08/21
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021	06/08/21
Carna Biosciences, Inc. announced that it has received ¥14.67507 million in funding from Cantor Fitzgerald & Co.	30/07/21
Carna Biosciences, Inc. announced that it expects to receive ¥14.67507 million in funding from Cantor Fitzgerald & Co.	14/07/21
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	12/02/21
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	12/02/21
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	09/11/20
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	09/11/20
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020	12/05/20
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020	12/05/20
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	07/02/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Carna Biosciences, Inc.

Azioni

4572

JP3220550002

Altre lingue

Filtri